Tan-Koi Wei Chuen is Assistant Professor and Lead of Regulatory System Strengthening in the Centre of Regulatory Excellence (CoRE) at the Duke-NUS Medical School. Wei Chuen collaborates with international stakeholders to address challenges in equitable access and safe use of health products. Her current research interests include regulatory systems strengthening, policy innovation, pharmacovigilance and pharmacogenomics. Notable consultancy work includes the Asian Development Bank commissioned project “Regional Support to Address the Outbreak of Coronavirus Disease 2019 and Potential Outbreaks of Other Communicable Diseases: Vaccine Regulation Firm”.
Prior to joining Duke-NUS Medical School, Wei Chuen was Regulatory Consultant and Team Lead of the Regulatory Research and Risk Communication teams at the Singapore’s Health Sciences Authority. Wei Chuen has also served as expert witness and has held appointments with Singapore's Ministry of Health and Asia-Pacific Economic Cooperation Pharmacovigilance Centre of Excellence Pilot Program.
A pharmacist by training, Wei Chuen received her doctoral degree from the Saw Swee Hock School of Public Health at the National University of Singapore under Singapore’s Health Manpower Development Plan (HMDP) Fellowship. Together with the Health Sciences Authority’s Regulatory Research and Risk Communication teams, Wei Chuen has received the Mrs Tan Shook Fong - PSS Innovation and Scientific Research Award as well as Health Sciences Authority Science & Innovation Day Outstanding Research Project awards.
Wei Chuen is currently focusing on regulatory systems strengthening. Her key projects include the CoRE-Asian Development Bank collaborative project, “Regional Support to Address the Outbreak of Coronavirus Disease 2019 and Potential Outbreaks of Other Communicable Diseases: Vaccine Regulation Firm”. The ADB-CoRE Vaccine Regulation project aims to inform the Asian Development Bank’s Health Sector Group about the regulatory landscape in Asia and the Pacific, focusing on regulatory systems strengthening and regulatory factors for vaccine manufacturing.
Research interest
- Regulatory systems strengthening
- Policy innovations
- Pharmacovigilance
- Pharmacogenomics
Selected publications and book chapter
- Promoting Collaboration of Regulators and Patients in Improving Drug Safety and Regulatory Decision Making. Khoo, Y.K., Lim, J.C.W., Tan-Koi, W.C. et al. Drug Safety (2023). https://doi.org/10.1007/s40264-023-01385-2
- Teng GG*, Tan-Koi WC*, Dong D, C Sung. Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease? Pharmacogenomics. 2020 Mar; 21(4):279-291. doi: 10.2217/pgs-2019-0160
- Tan-Koi, W., Leow, P. & Teo, Y. Applications of pharmacogenomics in regulatory science: a product life cycle review. Pharmacogenomics J 18, 359–366 (2018). https://doi.org/10.1038/tpj.2017.47
- Tan-Koi WC, Lim ES, Teo YY. Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment. Pharmacogenomics J. 2017 Mar;17(2):121-127. doi: 10.1038/tpj.2016.5
- Tan-Koi WC*, Sung C*, Chong YY, Lateef A, Pang SM, Vasudevan A, Aw D, Lui NL, Lee SX, Ren EC, Koay ES, Tay YK, Lim YL, Lee HY, Dong D, Loke C, Tan L, Limenta M, Lee EJ, Toh D, Chan CL. Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: A pharmacogenomics approach. Pharmacogenomics. 2017 Jun;18(9):881-890. doi: 10.2217/pgs-2017-0016
- Tan CW, Tan-Koi WC, Ng J, Chan CM, Hwang WY. A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02. Pharmacogenomics. 2016 Jul;17(11):1235-1243. doi: 10.2217/pgs-2016-0018
- Suwankesawong W, Dhippayom T, Tan- Koi WC, Kongkaew C. Pharmacovigilance activities in ASEAN countries. Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1061-9. doi: 10.1002/pds.4023
- Kapoor R, Tan-Koi WC, Teo YY. Role of pharmacogenetics in public health and clinical healthcare: A SWOT analysis. Eur J of Hum Genet. 2016 Dec;24(12):1651-1657. doi: 10.1038/ejhg.2016.114
- Dong D*, Tan-Koi WC*, Teng GG, Finkelstein E, Sung C. Cost-effectiveness analysis of genotyping for HLA-B*58:01 and an enhanced safety programme in gout patients starting allopurinol in Singapore. Pharmacogenomics. 2015 Nov;16(16):1781-93. doi: 10.2217/pgs.15.125
- Tan NWH, Pan WJ, Yunos HHBM, Tan WC, Lim KBL. Post-vaccination abscess requiring surgical drainage in a tertiary children’s hospital in Singapore. Pediatr Infect Dis J. 2010; 05(02):139-147. doi: 10.3233/JPI-2010-0239
Book Chapter
- Tan-Koi WC, Limenta M, EHM Mohamed, Lee EJ, Chapter 11 - The Importance of Ethnicity Definitions and Pharmacogenomics in Ethnobridging and Pharmacovigilance, Editor(s): Y. W. Francis Lam, Stuart A. Scott, Pharmacogenomics (Second Edition), Academic Press, 2019, Pages 289-327, ISBN 9780128126264, https://doi.org/10.1016/B978-0-12-812626-4.00011-5